Filana Therapeutics, Inc
Filana Therapeutics, Inc. is a clinical-stage biotechnology company based in Austin, Texas, focused on developing therapies for central nervous system disorders. Its lead program is simufilam, an oral small-molecule candidate being advanced for TSC-related epilepsy after the company discontinued its Alzheimer’s disease program in 2025.
Tilikausi 2025 · muutos edellisvuodesta
Kehitys 2020–2025
Liiketoiminta
Osuus liikevaihdostaSimufilam, the company's proprietary oral small-molecule candidate being developed for CNS disorders, especially TSC-related epilepsy.
Discovery and exploratory work to identify new indications and additional product candidates supported by experimental evidence.
Research and development work performed with universities, CROs, CDMOs, and other partners.
Asiakkaat
Filana does not currently sell approved products, so its near-term 'customers' are mainly regulators, clinical investigators, academic collaborators, and contract service providers that enable development. If approved in the future, the end customers would be physicians, patients, and payors in the CNS and epilepsy markets.
The company depends on FDA review, clinical hold resolution, and eventual marketing approval to advance simufilam.
Universities, academic collaborators, CROs, CDMOs, and clinical sites that perform outsourced studies and formulation work.
Neurologists, physicians, and patients in TSC-related epilepsy and other CNS indications who would use the drug if approved.
Commercial partners and reimbursement stakeholders that would support access, distribution, and market adoption after approval.
Strategia
The company is narrowing its focus to simufilam and TSC-related epilepsy after ending its Alzheimer’s program. Its strategy is to resolve the FDA clinical hold, generate proof-of-concept data, and preserve optionality through patents, collaborations, and potential licensing.
Clinical progress is blocked until the FDA hold is addressed, making this the key near-term value driver.
Positive clinical data would validate the mechanism and support future regulatory and partnering discussions.
The company has limited infrastructure and must conserve cash while advancing a high-risk pipeline.
Patent coverage is central to future partnering leverage and any eventual commercialization value.
Maantiede
Filana is headquartered in Austin, Texas and operates primarily from the United States. Its development footprint is global through patents, academic collaborations, and outsourced clinical and manufacturing partners, with intellectual property coverage mentioned in the U.S., Europe, Australia, Israel, Canada, Japan, and China.
Riskit
Filana is a pre-revenue biotech with a single lead program, so its value depends heavily on clinical, regulatory, and financing outcomes. The company also faces elevated legal, supply-chain, cybersecurity, and execution risks because it outsources much of its development work and remains under a clinical hold.
- FDA clinical hold on simufilamVaikutus: KriittinenTodennäköisyys: Korkea
The company cannot progress its TSC-related epilepsy program until the hold is lifted, directly affecting development timelines and value creation.
Kohdistuu: simufilam development program
- Single-asset pipeline concentrationVaikutus: KorkeaTodennäköisyys: Korkea
Most R&D is focused on simufilam, so any clinical or regulatory setback would have an outsized impact on the company.
Kohdistuu: pipeline concentration
- Legal proceedings and government inquiriesVaikutus: KorkeaTodennäköisyys: Korkea
Management discloses ongoing claims and inquiries, which can create direct costs and distract management.
Kohdistuu: litigation and regulatory matters
- Financing risk and cash burnVaikutus: KorkeaTodennäköisyys: Korkea
The company has no product revenue and expects significant future cash needs, increasing dilution or going-concern pressure if capital markets tighten.
Kohdistuu: funding and liquidity
- Dependence on third-party CROs, CDMOs, and clinical sitesVaikutus: KorkeaTodennäköisyys: Kohtalainen
The company outsources key development functions, so partner failures can delay studies, raise costs, or impair product quality.
Kohdistuu: outsourced development and supply chain
- Cybersecurity and data protectionVaikutus: KeskitasoTodennäköisyys: Matala
Clinical and IP data are sensitive, and breaches could disrupt operations or expose proprietary information.
Kohdistuu
Kirjanpito
Harkinnanvaraiset erätClinical trial, preclinical, and formulation costs are expensed as incurred, making reported losses sensitive to development timing.
Vaikutus: Period-to-period operating loss can swing with trial activity and outsourcing spend
Equity awards to employees and non-employees are a meaningful operating expense for a development-stage biotech.
Vaikutus: Can materially increase reported R&D and G&A expense
Management must estimate probable losses from claims and government inquiries, which involves significant judgment.
Vaikutus: Could affect liabilities and earnings if estimates change
The company has not generated product sales, so future revenue recognition will depend on approval, commercialization, or licensing terms.
Vaikutus: Current statements are driven by expenses rather than operating revenue
Samankaltaisia listattuja yhtiöitä
Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.
Larimar Therapeutics, Inc.
LRMR · Pharmaceutical Preparations
Serina Therapeutics, Inc.
SER · Pharmaceutical Preparations
Pasithea Therapeutics Corp.
KTTA · Pharmaceutical Preparations
Denali Therapeutics Inc.
DNLI · Biological Products, (No Diagnostic Substances)
Denali Therapeutics is a clinical-stage biopharmaceutical company developing barrier-crossing therapeutics for neurodegenerative and lysosomal storage diseases.
Septerna, Inc.
SEPN · Pharmaceutical Preparations
Septerna is a U.S.-based biotechnology company focused on discovering and developing small-molecule medicines for diseases driven by G protein-coupled receptors (GPCRs).
Gain Therapeutics, Inc.
GANX · Pharmaceutical Preparations
Päivitetty: 24.9.2026